News & Events about Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH Get Rating) major shareholder Brightstar Associates Llc bought 1,666,666 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Tuesday, January 24th. The shares were acquired at an average cost of $18.00 per share, for a ...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common...
Deciphera Pharmaceuticals (NASDAQ:DCPH Get Rating) had its target price hoisted by research analysts at Barclays from $8.00 to $9.00 in a note issued to investors on Wednesday, The Fly reports. The firm currently has an underweight rating on the stock. Barclayss price target points to a potential ...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT. A live webcast of the event will be available on the Events and...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH Get Rating) has earned an average rating of Moderate Buy from the eight ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has ...